Senate Hearings Probe FDA Authority On Drug Label Changes, Safety Trials
This article was originally published in The Tan Sheet
Executive Summary
Giving FDA the authority to require changes to drug labeling could help the agency get drug safety information to the public more quickly, FDA Office of New Drugs Deputy Director Sandra Kweder told the Senate Health Committee March 1
You may also be interested in...
Woodcock’s Message To OTC Industry: Innovation, Innovation, Innovation
Across the board innovation ranging from manufacturing to Rx switch programs is necessary for the OTC industry to spur growth in the future, according to FDA Acting Deputy Commissioner for Operations Janet Woodcock, MD
Woodcock’s Message To OTC Industry: Innovation, Innovation, Innovation
Across the board innovation ranging from manufacturing to Rx switch programs is necessary for the OTC industry to spur growth in the future, according to FDA Acting Deputy Commissioner for Operations Janet Woodcock, MD
Woodcock’s Message To OTC Industry: Innovation, Innovation, Innovation
Across the board innovation ranging from manufacturing to Rx switch programs is necessary for the OTC industry to spur growth in the future, according to FDA Acting Deputy Commissioner for Operations Janet Woodcock, MD